ASX:CSLBiotechs
Seqirus Spin-off Pause and Flu Demand Concerns Could Be A Game Changer For CSL (ASX:CSL)
In recent weeks, CSL has been in focus as investors look back on its February 11 half-year results and interim dividend announcement, following earlier cuts to its fiscal 2026 growth outlook and a pause to the planned Seqirus vaccines spin-off after weaker US flu vaccination rates.
At the same time, CSL has faced regulatory scrutiny over Tavneos data in Europe and tougher competition for its Vifor iron products, sharpening attention on how well the group can balance growth ambitions with...